APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Medications for Alcohol Use Disorder (AUD)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Medications for Alcohol Use Disorder (AUD) Market Analysis and Forecast 2026-2032

Report ID 174011310227 December 2025197 pages

Choose your research edition.

Industry ResearchMedications for Alcohol Use Disorder (AUD) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Medications for Alcohol Use Disorder (AUD) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Medications for Alcohol Use Disorder (AUD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medications for Alcohol Use Disorder (AUD) Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Medications for Alcohol Use Disorder (AUD) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Medications for Alcohol Use Disorder (AUD) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Medications for Alcohol Use Disorder (AUD) include Teva, Sun Pharmaceutical Industries, Merck KGaA, Mylan, Beijing Wellso Pharmaceutical Co, Zydus Pharmaceuticals, Taj Pharmaceuticals, TAGI Pharma Inc. and Rusan Pharma Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Medications for Alcohol Use Disorder (AUD), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Medications for Alcohol Use Disorder (AUD), also provides the revenue of main regions and countries. Of the upcoming market potential for Medications for Alcohol Use Disorder (AUD), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medications for Alcohol Use Disorder (AUD) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Medications for Alcohol Use Disorder (AUD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Medications for Alcohol Use Disorder (AUD) revenue, projected growth trends, production technology, application and end-user industry.

Medications for Alcohol Use Disorder (AUD) Segment by Company

Teva

Sun Pharmaceutical Industries

Merck KGaA

Mylan

Beijing Wellso Pharmaceutical Co

Zydus Pharmaceuticals

Taj Pharmaceuticals

TAGI Pharma Inc.

Rusan Pharma Ltd

Lundbeck

Glenmark Pharmaceuticals

Alvogen

Alkermes

Medications for Alcohol Use Disorder (AUD) Segment by Type

Acamprosate

Naltrexone

Disulfiram

Other

Medications for Alcohol Use Disorder (AUD) Segment by Application

Hospital

Rehabilitation Institutions

Others

Medications for Alcohol Use Disorder (AUD) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Alcohol Use Disorder (AUD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medications for Alcohol Use Disorder (AUD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Alcohol Use Disorder (AUD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Medications for Alcohol Use Disorder (AUD) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Medications for Alcohol Use Disorder (AUD) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Medications for Alcohol Use Disorder (AUD) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Medications for Alcohol Use Disorder (AUD) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Acamprosate Major Player Table 3. Naltrexone Major Player Table 4. Disulfiram Major Player Table 5. Other Major Player Table 6. Global Medications for Alcohol Use Disorder (AUD) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Rehabilitation Institutions Major Player Table 9. Others Major Player Table 10. Medications for Alcohol Use Disorder (AUD) Industry Trends Table 11. Medications for Alcohol Use Disorder (AUD) Industry Drivers Table 12. Medications for Alcohol Use Disorder (AUD) Industry Opportunities and Challenges Table 13. Medications for Alcohol Use Disorder (AUD) Industry Restraints Table 14. Global Medications for Alcohol Use Disorder (AUD) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Medications for Alcohol Use Disorder (AUD) Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Medications for Alcohol Use Disorder (AUD) Market Share by Region (2021-2026) Table 17. Global Medications for Alcohol Use Disorder (AUD) Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Medications for Alcohol Use Disorder (AUD) Market Share by Region (2027-2032) Table 19. Global Medications for Alcohol Use Disorder (AUD) Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Players (2021-2026) Table 21. Global Medications for Alcohol Use Disorder (AUD) Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Medications for Alcohol Use Disorder (AUD) Key Players Headquarters & Area Served Table 23. Global Medications for Alcohol Use Disorder (AUD) Players, Product Type & Application Table 24. Global Medications for Alcohol Use Disorder (AUD) Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Medications for Alcohol Use Disorder (AUD) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Medications for Alcohol Use Disorder (AUD) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Type (2021-2026) Table 31. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Type (2027-2032) Table 32. Global Medications for Alcohol Use Disorder (AUD) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Application (2021-2026) Table 36. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Application (2027-2032) Table 37. Teva Company Information Table 38. Teva Business Overview Table 39. Teva Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Teva Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 41. Teva Recent Development Table 42. Sun Pharmaceutical Industries Company Information Table 43. Sun Pharmaceutical Industries Business Overview Table 44. Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 46. Sun Pharmaceutical Industries Recent Development Table 47. Merck KGaA Company Information Table 48. Merck KGaA Business Overview Table 49. Merck KGaA Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 51. Merck KGaA Recent Development Table 52. Mylan Company Information Table 53. Mylan Business Overview Table 54. Mylan Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Mylan Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 56. Mylan Recent Development Table 57. Beijing Wellso Pharmaceutical Co Company Information Table 58. Beijing Wellso Pharmaceutical Co Business Overview Table 59. Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 61. Beijing Wellso Pharmaceutical Co Recent Development Table 62. Zydus Pharmaceuticals Company Information Table 63. Zydus Pharmaceuticals Business Overview Table 64. Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 66. Zydus Pharmaceuticals Recent Development Table 67. Taj Pharmaceuticals Company Information Table 68. Taj Pharmaceuticals Business Overview Table 69. Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 71. Taj Pharmaceuticals Recent Development Table 72. TAGI Pharma Inc. Company Information Table 73. TAGI Pharma Inc. Business Overview Table 74. TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 76. TAGI Pharma Inc. Recent Development Table 77. Rusan Pharma Ltd Company Information Table 78. Rusan Pharma Ltd Business Overview Table 79. Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 81. Rusan Pharma Ltd Recent Development Table 82. Lundbeck Company Information Table 83. Lundbeck Business Overview Table 84. Lundbeck Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Lundbeck Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 86. Lundbeck Recent Development Table 87. Glenmark Pharmaceuticals Company Information Table 88. Glenmark Pharmaceuticals Business Overview Table 89. Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 91. Glenmark Pharmaceuticals Recent Development Table 92. Alvogen Company Information Table 93. Alvogen Business Overview Table 94. Alvogen Medications for Alcohol Use Disorder (AUD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Alvogen Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 96. Alvogen Recent Development Table 97. Alkermes Company Information Table 98. Alkermes Business Overview Table 99. Alkermes Medications for Alcohol Use Disorder (AUD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Alkermes Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 101. Alkermes Recent Development Table 102. North America Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026) & (US$ Million) Table 108. North America Medications for Alcohol Use Disorder (AUD) Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country (US$ Million) & (2027-2032) Table 116. China Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026) & (US$ Million) Table 117. China Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032) & (US$ Million) Table 118. China Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026) & (US$ Million) Table 119. China Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia Medications for Alcohol Use Disorder (AUD) Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Medications for Alcohol Use Disorder (AUD) Image Figure 2. Global Medications for Alcohol Use Disorder (AUD) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medications for Alcohol Use Disorder (AUD) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Acamprosate Image Figure 5. Naltrexone Image Figure 6. Disulfiram Image Figure 7. Other Image Figure 8. Global Medications for Alcohol Use Disorder (AUD) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Medications for Alcohol Use Disorder (AUD) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Rehabilitation Institutions Image Figure 12. Others Image Figure 13. Global Medications for Alcohol Use Disorder (AUD) Market Size (US$ Million) & (2021-2032) Figure 14. Global Medications for Alcohol Use Disorder (AUD) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Medications for Alcohol Use Disorder (AUD) Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Medications for Alcohol Use Disorder (AUD) Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Type (2021-2032) Figure 21. Global Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Application (2021-2032) Figure 24. North America Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032) Figure 26. North America Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032) Figure 27. North America Medications for Alcohol Use Disorder (AUD) Revenue Share by Country (2021-2032) Figure 28. United States Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032) Figure 33. Europe Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032) Figure 34. Europe Medications for Alcohol Use Disorder (AUD) Revenue Share by Country (2021-2032) Figure 35. Germany Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032) Figure 45. China Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032) Figure 46. Asia Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032) Figure 48. Asia Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032) Figure 49. Asia Medications for Alcohol Use Disorder (AUD) Revenue Share by Region (2021-2032) Figure 50. Japan Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032) Figure 58. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032) Figure 59. SAMEA Medications for Alcohol Use Disorder (AUD) Revenue Share by Country (2021-2032) Figure 60. Brazil Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Medications for Alcohol Use Disorder (AUD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Acamprosate
  • Naltrexone
  • Disulfiram
  • Other
Applications
  • Hospital
  • Rehabilitation Institutions
  • Others
Companies covered
  • Teva
  • Sun Pharmaceutical Industries
  • Merck KGaA
  • Mylan
  • Beijing Wellso Pharmaceutical Co
  • Zydus Pharmaceuticals
  • Taj Pharmaceuticals
  • TAGI Pharma Inc.
  • Rusan Pharma Ltd
  • Lundbeck
  • Glenmark Pharmaceuticals
  • Alvogen
  • Alkermes

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Medications for Alcohol Use Disorder (AUD) Market by Type
  3. 1.2.1 Global Medications for Alcohol Use Disorder (AUD) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Acamprosate
  5. 1.2.3 Naltrexone
  6. 1.2.4 Disulfiram
  7. 1.2.5 Other
  8. 1.3 Medications for Alcohol Use Disorder (AUD) Market by Application
  9. 1.3.1 Global Medications for Alcohol Use Disorder (AUD) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Rehabilitation Institutions
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Medications for Alcohol Use Disorder (AUD) Market Dynamics
  1. 2.1 Medications for Alcohol Use Disorder (AUD) Industry Trends
  2. 2.2 Medications for Alcohol Use Disorder (AUD) Industry Drivers
  3. 2.3 Medications for Alcohol Use Disorder (AUD) Industry Opportunities and Challenges
  4. 2.4 Medications for Alcohol Use Disorder (AUD) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Medications for Alcohol Use Disorder (AUD) Market Perspective (2021-2032)
  2. 3.2 Global Medications for Alcohol Use Disorder (AUD) Growth Trends by Region
  3. 3.2.1 Global Medications for Alcohol Use Disorder (AUD) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Medications for Alcohol Use Disorder (AUD) Market Size by Region (2021-2026)
  5. 3.2.3 Global Medications for Alcohol Use Disorder (AUD) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Medications for Alcohol Use Disorder (AUD) Revenue by Players
  2. 4.1.1 Global Medications for Alcohol Use Disorder (AUD) Revenue by Players (2021-2026)
  3. 4.1.2 Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Medications for Alcohol Use Disorder (AUD) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Medications for Alcohol Use Disorder (AUD) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Medications for Alcohol Use Disorder (AUD) Key Players Headquarters & Area Served
  7. 4.4 Global Medications for Alcohol Use Disorder (AUD) Players, Product Type & Application
  8. 4.5 Global Medications for Alcohol Use Disorder (AUD) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Medications for Alcohol Use Disorder (AUD) Market CR5 and HHI
  11. 4.6.3 2025 Medications for Alcohol Use Disorder (AUD) Tier 1, Tier 2, and Tier 3
5 Medications for Alcohol Use Disorder (AUD) Market Size by Type
  1. 5.1 Global Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2032)
  3. 5.3 Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Type (2021-2032)
6 Medications for Alcohol Use Disorder (AUD) Market Size by Application
  1. 6.1 Global Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2032)
  3. 6.3 Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Medications for Alcohol Use Disorder (AUD) Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Sun Pharmaceutical Industries
  8. 7.2.1 Sun Pharmaceutical Industries Company Information
  9. 7.2.2 Sun Pharmaceutical Industries Business Overview
  10. 7.2.3 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Portfolio
  12. 7.2.5 Sun Pharmaceutical Industries Recent Developments
  13. 7.3 Merck KGaA
  14. 7.3.1 Merck KGaA Company Information
  15. 7.3.2 Merck KGaA Business Overview
  16. 7.3.3 Merck KGaA Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Portfolio
  18. 7.3.5 Merck KGaA Recent Developments
  19. 7.4 Mylan
  20. 7.4.1 Mylan Company Information
  21. 7.4.2 Mylan Business Overview
  22. 7.4.3 Mylan Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Medications for Alcohol Use Disorder (AUD) Product Portfolio
  24. 7.4.5 Mylan Recent Developments
  25. 7.5 Beijing Wellso Pharmaceutical Co
  26. 7.5.1 Beijing Wellso Pharmaceutical Co Company Information
  27. 7.5.2 Beijing Wellso Pharmaceutical Co Business Overview
  28. 7.5.3 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Portfolio
  30. 7.5.5 Beijing Wellso Pharmaceutical Co Recent Developments
  31. 7.6 Zydus Pharmaceuticals
  32. 7.6.1 Zydus Pharmaceuticals Company Information
  33. 7.6.2 Zydus Pharmaceuticals Business Overview
  34. 7.6.3 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
  36. 7.6.5 Zydus Pharmaceuticals Recent Developments
  37. 7.7 Taj Pharmaceuticals
  38. 7.7.1 Taj Pharmaceuticals Company Information
  39. 7.7.2 Taj Pharmaceuticals Business Overview
  40. 7.7.3 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
  42. 7.7.5 Taj Pharmaceuticals Recent Developments
  43. 7.8 TAGI Pharma Inc.
  44. 7.8.1 TAGI Pharma Inc. Company Information
  45. 7.8.2 TAGI Pharma Inc. Business Overview
  46. 7.8.3 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Portfolio
  48. 7.8.5 TAGI Pharma Inc. Recent Developments
  49. 7.9 Rusan Pharma Ltd
  50. 7.9.1 Rusan Pharma Ltd Company Information
  51. 7.9.2 Rusan Pharma Ltd Business Overview
  52. 7.9.3 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Portfolio
  54. 7.9.5 Rusan Pharma Ltd Recent Developments
  55. 7.10 Lundbeck
  56. 7.10.1 Lundbeck Company Information
  57. 7.10.2 Lundbeck Business Overview
  58. 7.10.3 Lundbeck Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Lundbeck Medications for Alcohol Use Disorder (AUD) Product Portfolio
  60. 7.10.5 Lundbeck Recent Developments
  61. 7.11 Glenmark Pharmaceuticals
  62. 7.11.1 Glenmark Pharmaceuticals Company Information
  63. 7.11.2 Glenmark Pharmaceuticals Business Overview
  64. 7.11.3 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
  66. 7.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 7.12 Alvogen
  68. 7.12.1 Alvogen Company Information
  69. 7.12.2 Alvogen Business Overview
  70. 7.12.3 Alvogen Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Alvogen Medications for Alcohol Use Disorder (AUD) Product Portfolio
  72. 7.12.5 Alvogen Recent Developments
  73. 7.13 Alkermes
  74. 7.13.1 Alkermes Company Information
  75. 7.13.2 Alkermes Business Overview
  76. 7.13.3 Alkermes Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Alkermes Medications for Alcohol Use Disorder (AUD) Product Portfolio
  78. 7.13.5 Alkermes Recent Developments
8 North America
  1. 8.1 North America Medications for Alcohol Use Disorder (AUD) Revenue (2021-2032)
  2. 8.2 North America Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2032)
  3. 8.2.1 North America Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026)
  4. 8.2.2 North America Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032)
  5. 8.3 North America Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032)
  6. 8.4 North America Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2032)
  7. 8.4.1 North America Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026)
  8. 8.4.2 North America Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032)
  9. 8.5 North America Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032)
  10. 8.6 North America Medications for Alcohol Use Disorder (AUD) Revenue by Country
  11. 8.6.1 North America Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026)
  13. 8.6.3 North America Medications for Alcohol Use Disorder (AUD) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Medications for Alcohol Use Disorder (AUD) Revenue (2021-2032)
  2. 9.2 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032)
  5. 9.3 Europe Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032)
  9. 9.5 Europe Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country
  11. 9.6.1 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Medications for Alcohol Use Disorder (AUD) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Medications for Alcohol Use Disorder (AUD) Revenue (2021-2032)
  2. 10.2 China Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2032)
  3. 10.2.1 China Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026)
  4. 10.2.2 China Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032)
  5. 10.3 China Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032)
  6. 10.4 China Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2032)
  7. 10.4.1 China Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026)
  8. 10.4.2 China Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032)
  9. 10.5 China Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Medications for Alcohol Use Disorder (AUD) Revenue (2021-2032)
  2. 11.2 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032)
  5. 11.3 Asia Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032)
  9. 11.5 Asia Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Country
  11. 11.6.1 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Medications for Alcohol Use Disorder (AUD) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue (2021-2032)
  2. 12.2 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country
  11. 12.6.1 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Medications for Alcohol Use Disorder (AUD) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst